Current known active infection with HIV, hepatitis B virus, or hepatitis C virus Known human immunodeficiency virus (HIV) or known active hepatitis B virus or hepatitis C virus infection Positive human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection. No known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus-I and -II positive status. Subjects with known active human immunodeficiency virus, hepatitis B virus, or hepatitis C virus infection Current known active infection with HIV, hepatitis B virus, or hepatitis C virus. Known active hepatitis A, B, or C virus infection Known infection with human immunodeficiency virus or chronic infection with hepatitis B virus (hepatitis B surface antigen positive) or hepatitis C virus (anti hepatitis C virus positive) Subjects with a known history of human immunodeficiency virus and , human T lymphotropic virus , hepatitis B virus, or active hepatitis C virus. Positive human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection. Known infection of, or who test positive for, human immunodeficiency virus, hepatitis B virus or hepatitis C virus. Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection Evidence of hepatitis B virus, hepatitis C virus or known HIV infection Evidence of hepatitis B virus, hepatitis C virus or known HIV infection Active HIV, hepatitis C virus, or hepatitis B virus infection(s) Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus (testing not required prior to enrollment)\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patients liver function tests fall within the parameters Known active hepatitis A, B or C virus infection Known history of human immunodeficiency virus (HIV) infection, active infection with hepatitis B virus or hepatitis C virus, or any uncontrolled active systemic infection Infection with human immunodeficiency virus (HIV) and/or chronic/active infection with hepatitis B virus or hepatitis C virus Has evidence of active hepatitis B virus or hepatitis C virus Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus. Known history of human immunodeficiency virus infection or an active hepatitis B or C virus infection (exception: this criteria does not apply to patients with cervical/anal tumours enrolling in Cohort ) Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection Known hepatitis B virus, hepatitis C virus or HIV infection Patients with a known active infection, e.g., hepatitis B virus or hepatitis C virus; human immunodeficiency virus (HIV)-positive patients who are otherwise well and who do not have evidence of significant immune compromise are eligible Has known active infection with hepatitis B virus or hepatitis C virus Must not have evidence of previous or current infection with hepatitis B virus Known active hepatitis C virus, or known active hepatitis B virus Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection Known hepatitis B virus, hepatitis C virus or HIV infection Positivity for human immunodeficiency virus (HIV)-/HIV-, Hepatitis B virus, and Hepatitis C virus active infection Known active infection with HIV, hepatitis B virus, or hepatitis C virus Positivity for human immunodeficiency virus (HIV)-/HIV-, hepatitis B virus, and hepatitis C virus active infection Active severe infection, or known chronic infection with human immunodeficiency virus (HIV), hepatitis B virus; patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence\r\nof cirrhosis AND the patients liver function tests fall within the parameters set Known hepatitis B virus, hepatitis C virus or HIV infection Subjects who have an active hepatitis B virus or hepatitis C virus infection requiring treatment as defined in the protocol Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation. Known active or chronic human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection, or positive hepatitis B (Hep B) surface antigen; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowed Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus; patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patients liver function tests fall within the parameters set above Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis Patients with active severe infection; known infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, or severe concurrent illness will be excluded from the study; HIV-positive patients on combination antiretroviral therapy are ineligible Patients with active severe infection; known infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, or severe concurrent illness Active infection with hepatitis A, B or C virus Known active hepatitis C virus, or known active hepatitis B virus Patients with known human immunodeficiency virus (HIV) or active infection with hepatitis C virus or hepatitis B virus (testing is not mandatory) Patients with active liver disease, for example, due to hepatitis B virus, hepatitis C virus, autoimmune hepatic disorder, or sclerosing cholangitis Known active infection with HIV or Hepatitis B or C virus Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation. Have active or uncontrolled clinically serious hepatitis B virus or hepatitis C virus infection. Known infection with HIV or chronic infection with hepatitis B virus or hepatitis C virus Evidence of hepatitis B virus, hepatitis C virus or known HIV infection Known history of human immunodeficiency virus (HIV), active hepatitis C virus, active hepatitis B\r\nvirus infection, or any uncontrolled active systemic infection \r\n* Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated Known active hepatitis C virus, or known active hepatitis B virus Known to be HIV positive, active hepatitis C virus, or active hepatitis B virus Active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or known active or chronic infection with human immunodeficiency virus; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection (including undetectable viral loads while on antiviral therapy) and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowed Patients with known active hepatitis B virus or hepatitis C virus acute or chronic infection Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection, or any uncontrolled active systemic infection \r\n* Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated Active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or known active or chronic infection with human immunodeficiency virus. Evidence of hepatitis B virus, hepatitis C virus or known HIV infection Known hepatitis B virus, hepatitis C virus or HIV infection Participants with known infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus Known history of human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antibiotics Patients with active liver disease, for example, due to hepatitis B virus, hepatitis C virus, autoimmune hepatic disorder, or sclerosing cholangitis Documentation of hepatitis B virus and hepatitis C virus serology is required Clinical evidence of active infection of any type, including hepatitis B or C virus Known hepatitis B virus, hepatitis C virus or HIV infection; Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patients liver function tests fall within the parameters set in inclusion criteria number c, hepatic function Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection Known history of human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antibiotics Active severe infection, or known chronic infection with human immunodeficiency virus (HIV), hepatitis B virus\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patients liver function tests fall within the parameters set Active infection with Hepatitis B virus or Hepatitis C virus Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection Known history of human immunodeficiency virus or active infection with hepatitis C virus or hepatitis B virus or any uncontrolled active systemic infection Known human immunodeficiency virus (HIV) infection or active hepatitis B virus or hepatitis C virus infection. Infection with Human immunodeficiency virus (HIV) or hepatitis B virus, hepatitis C\n virus Active hepatitis B and C virus infection Known active infection with hepatitis A, B or C virus Known history of infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive) A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus, or Hepatitis C Virus infection. Known intercurrent infections (including hepatitis C virus and human immunodeficiency virus or other conditions), or clinical evidence of these conditions Hepatitis B Virus, or Hepatitis C Virus infection (subjects with laboratory evidence of Hepatitis B Virus clearance may be enrolled). Known active infection with HIV, Hepatitis B or C virus Known active hepatitis B virus infection Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation. Known positive test for human immunodeficiency virus infection, hepatitis C virus, acute or chronic hepatitis B infection, or any co-morbid disease that would increase risk of toxicity. Currently known active infection with HIV, hepatitis B or C virus Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection Known history of human immunodeficiency virus (HIV) or active hepatitis C Virus or active hepatitis B virus infection or any uncontrolled active systemic infection Active hepatitis C virus Active hepatitis B or C virus Human Immunodeficiency Virus, Hepatitis B Virus or Hepatitis C Virus infection. Active infection with Hepatitis B virus or Hepatitis C virus Has acute or chronic active hepatitis B virus or hepatitis C virus infection or received treatment with nucleotide analogs such as those used in the treatment of hepatitis B virus (eg, lamivudine, adefovir, tenofovir, telbivudine, entecavir), ribavirin, or interferon alpha within weeks of initiation of study treatment. Has acute or chronic active hepatitis B virus or hepatitis C virus infection or received treatment with nucleotide analogs such as those used in the treatment of hepatitis B virus (eg, lamivudine, adefovir, tenofovir, telbivudine, and entecavir), ribavirin, or interferon alpha within weeks of initiation of study treatment.